Silexion Therapeutics Files 8-K on Financials
Ticker: SLXNW · Form: 8-K · Filed: Jan 14, 2025 · CIK: 2022416
Sentiment: neutral
Topics: financial-reporting, corporate-update
Related Tickers: SLXN
TL;DR
Silexion Therapeutics (SLXN) filed an 8-K updating its financial and operational status.
AI Summary
Silexion Therapeutics Corp. (formerly Biomotion Sciences) filed an 8-K on January 14, 2025, reporting on its results of operations and financial condition. The company, incorporated in the Cayman Islands and operating in the biological products sector, is headquartered in Ramat Gan, Israel. This filing is a routine update on its financial status and operational results.
Why It Matters
This 8-K filing provides investors with an update on Silexion Therapeutics Corp.'s financial condition and operational results, which is crucial for assessing the company's performance and future prospects.
Risk Assessment
Risk Level: low — This filing is a standard 8-K reporting financial and operational results, not indicating any immediate material adverse events.
Key Players & Entities
- Silexion Therapeutics Corp (company) — Registrant
- Biomotion Sciences (company) — Former company name
- January 14, 2025 (date) — Date of report
- Ramat Gan, Israel (location) — Principal executive offices
- Cayman Islands (location) — State of incorporation
FAQ
What is the primary purpose of this 8-K filing for Silexion Therapeutics Corp?
The primary purpose is to report on the company's Results of Operations and Financial Condition, as well as Financial Statements and Exhibits.
When was Silexion Therapeutics Corp. previously known by another name?
Silexion Therapeutics Corp. was formerly known as Biomotion Sciences, with a date of name change on May 6, 2024.
Where are Silexion Therapeutics Corp.'s principal executive offices located?
The principal executive offices are located at 12 Abba Hillel Road, Ramat-Gan, Israel, 5250606.
What is Silexion Therapeutics Corp.'s Standard Industrial Classification (SIC) code?
The SIC code for Silexion Therapeutics Corp. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
What is the Commission File Number for Silexion Therapeutics Corp?
The Commission File Number for Silexion Therapeutics Corp. is 001-42253.
Filing Stats: 692 words · 3 min read · ~2 pages · Grade level 13.2 · Accepted 2025-01-14 06:01:48
Key Financial Figures
- $0.0009 — registered Ordinary Shares, par value $0.0009 per share SLXN The Nasdaq Stock Mar
- $103.5 — Ordinary Shares at an exercise price of $103.5 per share SLXNW The Nasdaq Stock Ma
Filing Documents
- zk2432542.htm (8-K) — 50KB
- exhibit_99-1.htm (EX-99.1) — 1247KB
- exhibit_99-2.htm (EX-99.2) — 1164KB
- slxn_img01.jpg (GRAPHIC) — 37KB
- 0001178913-25-000102.txt ( ) — 2842KB
- slxn-20250114.xsd (EX-101.SCH) — 5KB
- slxn-20250114_def.xml (EX-101.DEF) — 18KB
- slxn-20250114_lab.xml (EX-101.LAB) — 27KB
- slxn-20250114_pre.xml (EX-101.PRE) — 20KB
- zk2432542_htm.xml (XML) — 6KB
02
Item 2.02 Results of Operations and Financial Condition. As previously reported, on November 14, 2024, Silexion Therapeutics Corp (the " Company ") issued a press release announcing its financial results for the fiscal quarter and nine months ended September 30, 2024. On that same day, the Company filed its quarterly report on Form 10-Q for the fiscal quarter ended September 30, 2024, which contained the Company's unaudited financial statements as of, and for the three and nine month periods ended on, September 30, 2024 (the " Q3 2024 Financials "). Also as previously reported, on November 27, 2024, the Company's Board of Directors, acting pursuant to the approval provided by the Company's shareholders at an extraordinary general meeting of the Company held on November 12, 2024 and, following adjournment, November 19, 2024, effected a 1-for-9 reverse share split of all of the Company's issued and outstanding, and authorized but unissued, ordinary shares (the " Reverse Share Split "). Following the Reverse Share Split, the Company has retroactively adjusted the share, per share and related option and warrant information included in the Q3 2024 Financials and in the Company's audited financial statements for the year ended December 31, 2023 (which reflect the results of Silexion Therapeutics Ltd., the Company's wholly-owned subsidiary and the Company's predecessor company from an accounting perspective) (the " 2023 Financials ") to reflect the reduced number of ordinary shares and the increased share price which resulted from the Reverse Share Split. The updated Q3 2024 Financials and 2023 Financials, reflecting the Reverse Split, are attached hereto as Exhibits 99.1 and 99.2, respectively, and are incorporated by reference into this Item 2.02.
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits 99.1 Updated unaudited financial statements of Silexion Therapeutics Corp as of, and for the three and nine month periods ended on, September 30, 2024 99.2 Updated audited financial SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SILEXION THERAPEUTICS CORP Date: January 14, 2025 By: /s/ Ilan Hadar Name: Ilan Hadar Title: Chief Executive Officer